ORIGINAL ARTICLE

Cough, airway inflammation, and mild asthma exacerbation

A B Chang, V A Harrhy, J Simpson, I B Masters, P G Gibson

Arch Dis Child 2002;86:270-275

See end of article for
authors' affiliations

Correspondence to:
A/Prof. A B Chang,
Flinders University NT
Clinical School, Alice
Springs Hospital, Northern
Territory 0870, Australia;
abchang@mac.com

Accepted
14 December 2001

Background: Prospective data on the temporal relation between cough, asthma symptoms, and airway inflammation in childhood asthma is unavailable.

Aims and methods: Using several clinical (diary, quality of life), lung function (FEV₁, FEV₁ variability, airway hyperresponsiveness), cough (diary, cough receptor sensitivity (CRS)), and inflammatory markers (sputum interleukin 8, eosinophilic cationic protein (ECP), myeloperoxidase; and serum ECP) of asthma severity, we prospectively described the course of these markers in children with asthma during a non-acute, acute, and resolution phase. A total of 21 children with asthma underwent these baseline tests; 11 were retested during days 1, 3, 7, and 28 of an exacerbation.

Results: Asthma exacerbations were characterised by increased asthma and cough symptoms and eosinophilic inflammation. Sputum ECP showed the largest increase and peaked later than clinical scores. Asthma scores consistently related to cough score only early in the exacerbation. Neither CRS nor cough scores related to any inflammatory marker.

Conclusion: In mild asthma exacerbations, eosinophilic inflammation is dominant. In asthmatic children who cough as a dominant symptom, cough heralds the onset of an exacerbation and increased eosinophilic inflammation, but cough scores and CRS do not reflect eosinophilic airway inflammation.

The severity of asthma can be categorised using several methods, such as assessment of clinical symptoms, pulmonary lung function indices (forced expiratory volume in one second (FEV₁) or its variability), degree of airway hyperresponsiveness (AHR), quality of life (QOL),¹ and sputum and serum inflammatory markers.² The relation between asthma symptoms and lung function variables can be poor. Airway inflammation has recently been recognised as a determinant of asthma symptoms and physiology, and some have advocated sputum rather than clinical indices as the outcome measure.³

Airway inflammation is a characteristic feature of acute severe exacerbations in asthmatic children where there is evidence of both eosinophilic and neutrophilic inflammation.⁴ Serum eosinophilic cationic protein (ECP) levels have been shown to correlate with clinical symptoms and FEV₁ in children, and some groups have advocated the use of serum and sputum ECP in disease monitoring.² In a prospective study of exacerbations in adults, sputum markers changed before clinical variables.⁵ However, there are no prospective data on the course and relation between these variable clinical and non-clinical markers of severity during a non-acute, acute, and resolution phase of childhood asthma. Childhood asthma differs from adult asthma in many distinctive ways, although they also share some common features.⁶ Understanding the course of the various markers of childhood asthma severity in mild and severe asthma exacerbations is important, as increasingly arguments are made for adequate anti-inflammatory treatment based on airway inflammation rather than on surrogates such as symptoms and spirometry.^{3,7,8} Studying mild asthma exacerbations is arguably more relevant as more children with asthma have such episodes rather than severe episodes requiring emergency attendance or hospitalisation.

Cough as a sole symptom has been equated to asthma, and included in asthma severity scales.¹ Recent literature has questioned this approach,^{9,10} and contemporary asthma diary scores have removed isolated cough.¹¹ It has been established

that in human airways, the pathways for cough and bronchoconstriction are distinctly different.^{12,13} Nevertheless, clinically it is well known that in some children, cough heralds the onset of an asthma exacerbation and alterations in cough receptor sensitivity (CRS) have been shown in those who cough with their asthma episodes.¹⁴ Furthermore, cough can be the sole manifestation of eosinophilic airway inflammation in adults with cough variant asthma and eosinophilic bronchitis.¹⁵ The relation between CRS, subjective cough scores, and airway inflammation is unknown in childhood asthma. In particular, to the authors' knowledge, there is no published study that has prospectively defined the temporal relation between cough, asthma symptoms, and airway inflammation in a group of children with classical clinical asthma. The aims of this study were: (1) to examine and relate common asthma indices (QOL, AHR, lung function, asthma diary) with cough indices (CRS, cough diary) and markers of eosinophilic and neutrophilic inflammation (serum ECP, sputum ECP, interleukin 8 (IL-8), myeloperoxidase (MPO)) in children with asthma during a non-acute, acute, and resolution phase of asthma; and (2) to determine if baseline markers' clinical or inflammatory parameters could predict future asthma exacerbation. We hypothesised that the time sequence of airway inflammation would differ from asthma and cough symptoms.

METHODS

Children with classical clinical asthma (recurrent airways obstruction manifested by wheeze and dyspnoea relieved by bronchodilator therapy) aged 5.5-16 years were recruited

Abbreviations: AHR, airway hyperresponsiveness; CRS, cough receptor sensitivity; ECP, eosinophilic cationic protein; ETS, environmental tobacco smoke; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; HS, hypertonic saline; IL, interleukin; IQR, interquartile range; MPO, myeloperoxidase; QOL, quality of life

from the outpatient department. Children with any chronic disease (other than asthma) were excluded. The children were tested when well (no respiratory tract infection or exacerbation of asthma for at least four weeks) during baseline. A clinical history was obtained and a repeatable question of cough dominant asthma was utilised.¹⁴ At baseline, the children underwent: venipuncture for ECP (serum ECP), skin prick test, spirometry, capsaicin CRS test,¹⁶ hypertonic saline (HS) test, induced sputum, and FEV₁ measured twice a day on a pocket digital spirometer (Vitalograph 2110 Electronic Diary, Buckingham, UK) for a week. The children and parents also kept separate daily daytime diaries for cough and asthma symptoms. The validated cough scale utilised a verbal descriptive score of daytime coughs, ranging from 0 (no cough) to 5 (cannot perform most usual daytime activity because of severe coughing).¹⁷ The asthma score was the average of four questions,¹¹ and the children and parents excluded the cough component of their asthma symptoms in the asthma diary score. Children and parents completed the child and carer's QOL questionnaire respectively.^{18,19} History of environmental tobacco smoke (ETS) exposure was obtained; urine cotinine levels were measured using gas chromatography with deuterated cotinine as an internal standard.

Subjects were retested on days 1 (D1), 3 (D3), 7 (D7), and 28 (D28) of an asthma exacerbation (increased wheeze, chest tightness, and requirement for additional bronchodilator medications for more than eight hours). The study was carried out between February 1999 and January 2000. During repeat visits, all tests except the skin prick test were repeated. D1 tests were done before any additional steroids were taken. Exacerbation surveillance was done on diary cards and telephone reminders. On a monthly basis, new diary cards were sent, and the preceding month's diary card returned. Written consent was obtained from the parent(s) and the study was approved by the local hospital's Ethics Committee for Human Research.

Tests

Serum ECP was processed by a dedicated service on site using radioimmunoassay (Pharmacia & Upjohn, Uppsala, Sweden). Skin prick test was performed using six allergens, and negative and positive controls.²⁰ Medications were withheld prior to all tests.²¹ Spirometry (Cosmed Kit, Italy) was performed in a sitting erect position with a nose clip. Outcome measures of capsaicin CRS test performed with regulation of the inspiratory flow¹⁶ were C2 and C5 (lowest concentration of capsaicin that stimulated ≥ 2 coughs and ≥ 5 coughs respectively). The standardised 4.5% HS challenge was used.²¹ Presence of AHR (AHR positive) was defined as a fall in FEV₁ of $\geq 15\%$ from baseline. Children were encouraged to cough and expectorate after each HS nebulisation. Sputum collected was processed immediately in the standardised manner.⁴

Statistical analysis

Statistical software package SPSS version 7.5 (Chicago, USA) was utilised. For continuous variables, the Mann-Whitney test was used for unpaired data and the Wilcoxon test for paired data. When repeated measurements were made, the Friedman and Kruskal-Wallis tests were utilised for paired and unpaired data respectively. Spearman correlation (r_s) was used for correlation. A two tailed p value of ≤ 0.05 was considered significant. Logistic regression was utilised for prediction of the development of an asthma exacerbation within the follow up period.

RESULTS

Twenty one children were recruited (16 boys, five girls; median age 10.8 years, interquartile range (IQR) 3.9). Only 11 of the 21 children had an exacerbation of their asthma during the observation period of 175 person months. The median age of these 11 children (nine boys, two girls) was 10.53 years (IQR 3.9). All but one were atopic, nine were on regular inhaled corticosteroids, three on cromolyns, and four on long acting β_2

Table 1 Spirometer indices, AHR, and clinical markers during baseline and an exacerbation of asthma

	Baseline (n=11)	Day 1 (n=11)	p*	Day 3 (n=11)	p†	Day 7 (n=11)	p‡	Day 28 (n=11)	p§
Asthma score (child recorded)	0.2 (0, 0.89)	1.75 (0.75, 5)	0.02	1.5 (0.25, 2.75)	0.11	0 (0, 0.75)	0.87	0 (0, 0)	0.00001
Asthma score (parent recorded)	0.2 (0, 0.88)	1.75 (1.25, 4.5)	0.008	1 (0.25, 3.75)	0.04	0 (0, 0.25)	0.21	0 (0, 0)	0.00001
Cough score (child recorded)	0.66 (0.22, 1.44)	3.5 (2, 4)	0.005	2 (1.75, 4)	0.037	1 (0, 1)	0.72	0 (0, 0)	0.00001
Cough score (parent recorded)	0.71 (0, 1.44)	3 (2, 4)	0.003	2 (2, 4)	0.01	1 (0, 2)	0.51	0 (0, 0)	0.00001
Child's QOL	6.7 (5, 7)	5.5 (5.1, 6.3)	0.4	5.6 (5.1, 6.1)	0.24	6.1 (5.5, 6.3)	0.88	7 (6.7, 7)	0.19
Parents' QOL	6 (4.9, 6.7)	5.6 (4.7, 6)	0.16	5.5 (5.1, 5.9)	0.81	5.8 (5.2, 6.6)	0.88	6.4 (5.8, 7)	0.71
FEV ₁ % predicted	88 (76, 100)	85.5 (71, 92)	0.66	85.5 (62, 92)	0.213	87.4 (83, 98)	0.33	87.4 (76, 90)	0.25
FVC % predicted	94.5 (85, 106)	90.7 (83, 97)	0.09	89.5 (75, 105)	0.09	95.4 (89, 113)	0.72	95.4 (88, 108)	0.12
FEV ₁ variability %	7.4 (3, 11.3)	14.5 (4.3, 23.7)	0.06	4.6 (2.7, 17.1)	0.28	8.5 (5.2, 27)	0.07	4.6 (2.4, 9.9)	0.18
AHR positive, n (%)	2 (18%)	3 (30%)	0.23	3 (30%)	0.5	1 (10%)	1.0	4 (40%)	0.3

Results expressed as median (quartiles).

*Wilcoxon test between baseline and day 1 data; †Wilcoxon test between baseline and day 3 data; ‡Wilcoxon test between baseline and day 7 data;

§Friedman test for baseline, day 1, day 3, and day 7 data.

Table 2 Cough receptor sensitivity and inflammatory markers during baseline and an exacerbation of asthma

	Baseline (n=11)	Day 1 (n=11)	p*	Day 3 (n=11)	p†	Day 7 (n=11)	p‡	Day 28 (n=11)	p§
C5	110 (n=11) (39, 547)	78 (n=11) (17, 195)	0.17	39 (n=11) (19, 156)	0.08	78 (n=11) (39, 312)	0.61	39 (n=11) (19, 78)	0.15
% Sputum eosinophils	2.8 (n=10) (1.2, 7.9)	6.42 (n=8) (2.6, 8.4)	0.8	3.6 (n=8) (0.8, 12.9)	0.34	7.5 (n=9) (0.9, 3.4)	0.21	3.64 (n=10) (0.9, 8.9)	0.19
% Sputum neutrophils	8.4 (n=10) (4.8, 23.2)	28.3 (n=8) (13.2, 56.1)	0.33	8.0 (n=8) (7, 29.3)	0.4	36.8 (n=9) (12, 60.8)	0.07	9.7 (n=10) (6.3, 22.8)	0.69
Sputum ECP (ng/ml)	151 (n=10) (33.1, 460)	457 (n=8) (233, 855)	0.017	1154 (n=8) (129, 3927)	0.01	288.6 (n=9) (45, 1439)	0.05	335 (n=10) (27, 733)	0.027
IL-8 (ng/ml)	0.76 (n=10) (0.39, 2.12)	1.69 (n=8) (0.79, 12.8)	0.11	6.21 (n=8) (2.77, 12.2)	0.09	1.39 (n=8) (0.65, 5.82)	0.5	0.92 (n=10) (0.66, 3.97)	0.27
MPO (mg/ml)	24.5 (n=9) (16.8, 45.5)	53.6 (n=8) (19.3, 79.3)	0.17	14.4 (n=7) (19.8, 54)	1.0	14.4 (n=9) (14.1, 35.1)	1.0	26.2 (n=10) (14.4, 215)	0.2
Serum ECP (µg/l)	34.5 (n=10) (27.3, 59.3)	45 (n=10) (15, 79.3)	0.24	33 (n=10) (21, 73)	1.0	288.6 (n=9) (14.5, 44)	0.07	335 (n=10) (19.5, 52)	0.12

Results expressed as median (quartiles).

*Wilcoxon test between baseline and day 1 data; †Wilcoxon test between baseline and day 3 data; ‡Wilcoxon test between baseline and day 7 data;

§Friedman test for baseline, day 1, day 3, and day 7 data.

agonists. Six children had passive tobacco smoke exposure and five did not. All but one child had cough as a significant symptom with their asthma episodes. None were hospitalised for their asthma exacerbation, four children were treated with a course of oral steroids, three with doubling their inhaled steroid dose, and the remaining four were managed with increased use of salbutamol (3–4 hourly for several days). The median length of time from baseline to D1 was 1.5 months (IQR 1.0). There was no significant difference in the length of follow up between those with (median 21.3 months, IQR 0.9) and without an asthma exacerbation (median 20.9 months, IQR 2.2).

At the onset of the exacerbation (D1), cough and asthma symptoms significantly increased ($p = 0.00001$). Sputum ECP also significantly increased and sputum eosinophils were increased ($>2.5\%$) in all but one child. Trends were seen in FEV_1 fall and FEV_1 variability but were not significant. Table 1 shows the course of asthma scores, cough scores, QOL, spirometry, and AHR indices at baseline and during the exacerbation. Table 2 shows those of CRS, serum, and sputum indices. The trend of the various markers shows a non-concurrent peak; serum ECP and C2 peaked on D1, but non-significantly when compared to baseline. These peaks were concurrent with diary symptoms asthma and cough scores on D1. Sputum ECP significantly peaked on D3 by an increase of more than 10-fold. IL-8 and MPO did not significantly change during asthma exacerbation. Cough and asthma scores between baseline and D1 for both child and parent scores were significantly different. Comparing D3 and baseline, significant differences were found for both scores in parent recorded diaries and child recorded cough score but not in child recorded asthma score. There was no significant difference between exacerbation and baseline scores in QOL, all spirometry indices, AHR, and CRS.

CRS outcome measures (C2 and C5) did not correlate to any marker of clinical severity (asthma score, cough score, QOL), pulmonary function indices (FEV_1 , forced vital capacity (FVC), FEV_1 variability) or inflammatory marker (IL-8, serum ECP, sputum ECP, serum eosinophils, sputum eosinophils, sputum neutrophils, MPO) of asthma during any of the test days (baseline, D1, D3, D7, and D28). At baseline and D1, there was a strong correlation between cough and asthma score, as recorded by the child and parent(s) (tables 3 and 4). On D3

and D7, this relation was lost except for that between child recorded asthma score with parent recorded cough score on D3, and between parent recorded asthma score with child recorded cough score on D7.

On logistic regression, no baseline factor could significantly predict the asthma exacerbation.

The mean urine cotinine in ETS exposed children was 94.3 (SEM 91) ng/ml and that in ETS non-exposed was 1 (SEM 0) ng/ml (mean difference 93, $p = 0.037$). Smoke exposure did not significantly influence any inflammatory marker on any test day. At baseline but not during exacerbation test days, child recorded asthma and cough scores and parent recorded cough scores were significantly higher in ETS exposed children when compared to ETS non-exposed children (table 5).

DISCUSSION

This study has described the course of various markers of cough and asthma, spirometry indices, and airway inflammation in childhood asthma, from baseline to an acute mild exacerbation and resolution state. The mild exacerbations were characterised by an increase in symptoms and airway inflammation, with non-significant changes in lung function. Only sputum ECP showed a significant increase during the exacerbation, and peaked later than clinical scores. Asthma scores consistently related to cough score only in the very early stages of the exacerbation. We have also shown that neither CRS nor cough scores relate to any of the inflammatory markers measured, and that spirometry, AHR, and FEV_1 variability were insensitive markers of mild asthma exacerbations. Lastly, baseline measurements could not predict the development of an exacerbation within the follow up time of 175 person months.

We have previously shown that in acute severe asthma, airway inflammation is characterised by infiltration of both eosinophils and neutrophils.⁴ In the present study where mild exacerbations were studied, eosinophilic but not neutrophilic inflammation was present (evidenced by D1 sputum eosinophils $>2.5\%$, increase in sputum ECP but not IL-8 or MPO). This raises the question of whether the more common occurrence of mild asthma exacerbations in childhood differs from the less common severe exacerbations. In adults, neutrophilic inflammation occurs in the more severe forms of asthma,^{22, 23}

Table 3 Correlation between the different markers at baseline and day 1 of asthma exacerbation

	Asthma score (parent recorded)	Cough score (child recorded)	Cough score (parent recorded)	Child's QOL	Parents' QOL	IL-8	Sputum ECP
Baseline							
Asthma score (child recorded)	0.93 (0.0001)	0.81 (0.002)	0.84 (0.001)	-0.91 (0.0001)	-0.76 (0.006)	0.1 (0.7)	0.32 (0.37)
Asthma score (parent recorded)		0.91 (0.0001)	0.91 (0.0001)	-0.934 (0.0001)	-0.8 (0.003)	-0.12 (0.74)	0.4 (0.25)
Cough score (child recorded)			0.96 (0.0001)	-0.78 (0.005)	-0.73 (0.011)	-0.32 (0.36)	0.54 (0.11)
Cough score (parent recorded)				-0.73 (0.001)	-0.73 (0.012)	-0.41 (0.24)	0.24 (0.51)
Child's QOL					0.7 (0.017)	0.08 (0.81)	-0.29 (0.42)
Parents' QOL						-0.21 (0.55)	-0.03 (0.9)
IL-8							-0.08 (0.83)
Day 1							
Asthma score (child recorded)	0.75 (0.008)	0.88 (0.001)	0.84 (0.001)	-0.014 (0.97)	0.24 (0.48)	-0.76 (0.031)	-0.83 (0.01)
Asthma score (parent recorded)		0.75 (0.013)	0.78 (0.004)	-0.27 (0.43)	-0.22 (0.51)	-0.79 (0.02)	-0.76 (0.03)
Cough score (child recorded)			0.97 (0.0001)	0.11 (0.76)	0.19 (0.6)	-0.43 (0.29)	-0.58 (0.13)
Cough score (parent recorded)				-0.27 (0.43)	0.2 (0.56)	0.55 (0.16)	-0.58 (0.14)
Child's QOL					0.51 (0.11)	0.29 (0.49)	-0.17 (0.69)
Parents' QOL						0.12 (0.48)	-0.14 (0.74)
IL-8							0.43 (0.34)

Results expressed as Spearman correlation (two tailed p value).

and typically reflects an infective cause.²⁴ Eosinophilic exacerbations can be triggered by allergen exposure or non-compliance with corticosteroid therapy.²⁵

Poor agreement between clinical judgement (symptoms, spirometry) and airway inflammatory component assessed by sputum cell counts has been recently described in adults with asthma.³ We have also shown that asthma symptoms related poorly to most inflammatory markers in mild exacerbations of childhood asthma. The relation between sputum ECP and asthma was significant but negatively associated; as asthma symptoms were subsiding, sputum ECP was at its peak. In cross sectional studies, sputum ECP and serum ECP related to FEV₁,² but in this small prospective study, the relation was not found. In this study of mild asthma exacerbations, changes in AHR, FEV₁, and FEV₁ variability were insensitive measures, when compared to sputum ECP and symptom perception. Although the trend of QOL in both child and parents reflected asthma scores, the changes were insignificant. This would be expected for this acute setting as QOL is insensitive for short term effects. We were unable to define any factors that could predict the development of an asthma exacerbation within the follow up period. As viral infections are the commonest cause of asthma exacerbations in children,²⁶ this finding is not surprising. However, this study is limited by small numbers and a relatively short follow up period. Martinez argues that in an individual patient (in contrast to research), single markers for childhood asthma with its various phenotypes are unlikely to be useful as they are context and time variant dependent.⁷ This study cannot answer the question of the usefulness of the various markers of asthma in an individual patient, but the data presented support the sensitivity of sputum ECP when compared to other indices of asthma severity.

Although cough features prominently in asthma management plans, whether the presence of cough does indeed herald the onset of an asthma exacerbation has never been shown prospectively. This study has shown this is indeed true in a selected group of children, whose parents had previously indicated that cough was a significant symptom with their asthma episodes. We were unable to compare coughers versus non-coughers because of the small sample size. Although we used a validated cough score chart,¹⁷ this finding is also limited by the lack of an objective cough monitor, as symptoms reflect perception, which is known to be dependent on the population studied.²⁷ Nevertheless we found no relation between CRS and asthma inflammatory markers, again raising the question whether cough should be used as a marker of asthma severity in the non-acute asthma. The occurrence of cough without an increase in CRS may be related to an irritant effect or cough receptor activation by eosinophilic activates.²⁸ The reduction in cough symptoms while sputum ECP was still raised (D3) could be a result of temporal adaptation to the cough stimulus.^{29, 30} In this study CRS measures did not change, unlike our previous study which described increased cough sensitivity during the coughing period in hospitalised children with asthma.¹⁴ We postulate this difference relates to the different asthma exacerbations studied (mild versus severe exacerbation where neutrophilic airway inflammation occurs⁴), and possibly to the small sample size.

Children with ETS exposure were more likely to have higher asthma and cough scores at baseline but not during an exacerbation. We did not find any difference in the inflammatory markers. A three hour ETS exposure did not change cellular and inflammatory markers (ECP, MPO, tryptase, prostanoids, and leukotrienes) in bronchoalveolar lavage fluid and FEV₁,

Table 4 Correlation between the different markers on days 3 and 7 of asthma exacerbation

	Asthma score (parent recorded)	Cough score (child recorded)	Cough score (parent recorded)	Child's QOL	Parents' QOL	IL-8	Sputum ECP
Day 3							
Asthma score (child recorded)	0.86 (0.001)	0.62 (0.06)	0.64 (0.03)	0.33 (0.39)	-0.25 (0.57)	-0.58 (0.13)	-0.25 (0.55)
Asthma score (parent recorded)		0.41 (0.23)	0.55 (0.08)	0.3 (0.43)	-0.14 (0.74)	-0.69 (0.06)	-0.24 (0.57)
Cough score (child recorded)			0.89 (0.001)	0.07 (0.39)	-0.26 (0.57)	0.03 (0.95)	-0.42 (0.3)
Cough score (parent recorded)				0.24 (0.53)	-0.26 (0.53)	-0.06 (0.9)	-0.07 (0.87)
Child's QOL					0.24 (0.57)	-0.43 (0.4)	-0.37 (0.47)
Parents' QOL						-0.8 (0.1)	-0.7 (0.19)
IL-8							0.41 (0.32)
Day 7							
Asthma score (child recorded)	0.71 (0.01)	0.37 (0.06)	0.18 (0.61)	-0.09 (0.79)	0.55 (0.67)	-0.47 (0.28)	-0.45 (0.23)
Asthma score (parent recorded)		0.61 (0.045)	0.42 (0.2)	0.2 (0.56)	-0.33 (0.32)	-0.43 (0.33)	-0.49 (0.18)
Cough score (child recorded)			0.8 (0.003)	0.7 (0.016)	0.16 (0.65)	-0.03 (0.94)	-0.05 (0.89)
Cough score (parent recorded)						0 (1)	0.04 (0.91)
Child's QOL						0 (1)	0.84 (0.005)
Parents' QOL						-0.14 (0.76)	0.01 (0.98)
IL-8							0.89 (0.007)

Results expressed as Spearman correlation (two tailed p value).

but increased symptoms in adults with mild asthma.³¹ The lack of difference could be related to the small subject numbers or more likely, the appropriate inflammatory marker was not measured. In animal studies, ETS exposure primarily causes neurogenic inflammation,³² which is arguably important in the symptom perception of cough and chest tightness.³³

We conclude that in mild asthma exacerbations in children, eosinophilic inflammation is dominant, and that the commonly used clinical indices of asthma, FEV₁, FEV₁ variability, and AHR are insensitive markers. These markers could not predict the development of an asthma exacerbation. In the subgroup of children with asthma (those with cough dominant asthma), the presence of cough heralds the onset of an exacerbation and increased eosinophilic inflammation, but cough scores and CRS do not reflect eosinophilic inflammation during the course of the exacerbation. Whether cough scores and CRS reflect neutrophilic airway inflammation in severe childhood asthma exacerbations is unknown.

Table 5 Cough and asthma scores in ETS exposed and non-exposed children

	ETS exposed	Non-ETS exposed	p value
Child recorded			
Asthma score	0.9 (0.2, 1.8)	0 (0, 2.2)	0.035
Cough score	1.4 (0.6, 2.6)	0.3 (0.1, 0.8)	0.028
Parent recorded			
Asthma score	0.5 (0.1, 1.7)	0.1 (0, 0.2)	0.08
Cough score	1.4 (0.6, 2.3)	0.1 (0, 0.8)	0.027

Results expressed as median (quartiles).

ACKNOWLEDGEMENTS

We thank Peter Dash (cytology department) for performing the cell differential counts and Dr Melissa Hubbard for her assistance in examining some children during their asthma exacerbation. The project was supported in part by The Sylvia and Charles Viertel Charitable Trust.

Authors' affiliations

A B Chang, Flinders University NT Clinical School, Alice Springs Hospital, Northern Territory
V A Harry, Department of Respiratory Medicine, Mater Children's Hospital
J Simpson, P G Gibson, Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, NSW
I B Masters, Department of Respiratory Medicine, Royal Children's Hospital, Herston, Queensland

REFERENCES

- 1 Rosier MJ, Bishop J, Nolan T, et al. Measurement of functional severity of asthma in children. *Am J Respir Crit Care Med* 1994;**149**:1434-41.
- 2 Turktaş I, Demirsoy S, Koc E, et al. Effects of inhaled steroid treatment on serum eosinophilic cationic protein (ECP) and low affinity receptor for IgE (Fc epsilon R1/CD23) in childhood bronchial asthma. *Arch Dis Child* 1996;**75**:314-18.
- 3 Parameswaran K, Pizzichini E, Pizzichini MM, et al. Clinical judgement of airway inflammation versus sputum cell counts in patients with asthma. *Eur Respir J* 2000;**15**:486-90.
- 4 Norzila MZ, Fakes K, Henry RL, et al. Interleukin-8 secretion and neutrophil recruitment accompanies induced sputum eosinophil activation in children with acute asthma. *Am J Respir Crit Care Med* 2000;**161**:769-74.
- 5 Pizzichini MM, Pizzichini E, Clelland L, et al. Prednisone-dependent asthma: inflammatory indices in induced sputum. *Eur Respir J* 1999;**13**:15-21.
- 6 Busse W, Banks-Schlegel SP, Larsen GL. Childhood- versus adult-onset asthma. *Am J Respir Crit Care Med* 1995;**151**:1635-9.
- 7 Martinez FD. Context dependency of markers of disease. *Am J Respir Crit Care Med* 2000;**162**:565-575.

- 8 **Bush A**, Tiddens H, Silverman M. Clinical implications of inflammation in young children. *Am J Respir Crit Care Med* 2000;**162**:S11–S14.
- 9 **McKenzie S**. Cough—but is it asthma? *Arch Dis Child* 1994;**70**:1–2.
- 10 **Chang AB**. State of the art: cough, cough receptors, and asthma in children. *Pediatr Pulmonol* 1999;**28**:59–70.
- 11 **Santanello NC**, Barber BL, Reiss TF, *et al*. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. *Eur Respir J* 1997;**10**:646–51.
- 12 **Fuller RW**, Karlsson J-A, Choudry NB, Pride NB. Effect of inhaled and systemic opiates on responses to inhaled capsaicin in humans. *J Appl Physiol* 1988;**65**:1125–30.
- 13 **Choudry NB**, Fuller RW, Anderson N, Karlsson J-A. Separation of cough and reflex bronchoconstriction by inhaled local anaesthetics. *Eur Respir J* 1990;**3**:579–83.
- 14 **Chang AB**, Phelan PD, Robertson CF. Cough receptor sensitivity in children with acute and non-acute asthma. *Thorax* 1997;**52**:770–4.
- 15 **Gibson PG**, Hargreave FE, Girgis-Gabardo A, *et al*. Chronic cough with eosinophilic bronchitis: examination for variable airflow obstruction and response to corticosteroid. *Clin Exp Allergy* 1995;**25**:127–32.
- 16 **Chang AB**, Phelan PD, Roberts RGD, Robertson CF. Capsaicin cough receptor sensitivity test in children. *Eur Respir J* 1996;**9**:2220–3.
- 17 **Chang AB**, Newman RG, Carlin J, *et al*. Subjective scoring of cough in children: parent-completed vs child-completed diary cards vs an objective method. *Eur Respir J* 1998;**11**:462–6.
- 18 **Juniper EF**, Guyatt GH, Feeny DH, *et al*. Measuring quality of life in children with asthma. *Qual Life Res* 1996;**5**:35–46.
- 19 **Juniper EF**, Guyatt GH, Feeny DH, *et al*. Measuring quality of life in the parents of children with asthma. *Qual Life Res* 1996;**5**:27–34.
- 20 **Dreborg S**. Bronchial hyper-reactivity and skin sensitivity. *Clin Exp Allergy* 1991;**21**:529.
- 21 **Chang AB**, Phelan PD, Holst D, Robertson CF. Effect of capsaicin on airway responsiveness to hypertonic saline challenge in asthmatic and non-asthmatic children. *Pediatr Pulmonol* 1997;**23**:412–16.
- 22 **Hargreave FE**, Leigh R. Induced sputum, eosinophilic bronchitis, and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999;**160**:S53–S57.
- 23 **Sur S**, Crotty TB, Kephart GM, *et al*. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? *Am Rev Respir Dis* 1993;**148**:713–19.
- 24 **Pizzichini MM**, Pizzichini E, Efthimiadis A, *et al*. Asthma and natural colds. Inflammatory indices in induced sputum: a feasibility study. *Am J Respir Crit Care Med* 1998;**158**:1178–84.
- 25 **Jayaram L**, Parameswaran K, Sears MR, Hargreave FE. Induced sputum cell counts: their usefulness in clinical practice. *Eur Respir J* 2000;**16**:150–8.
- 26 **Johnston SL**, Pattemore PK, Sanderson G, *et al*. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. *BMJ* 1995;**310**:1225–9.
- 27 **Chang AB**, Phelan PD, Robertson CF, *et al*. Frequency and perception of cough severity. *J Paediatr Child Health* 2001;**37**:142–5.
- 28 **Ogawa H**, Fujimura M, Saito M, *et al*. The effect of the neurokinin antagonist FK-224 on the cough response to inhaled capsaicin in a new model of guinea-pig eosinophilic bronchitis induced by intranasal polymyxin B. *Clin Auton Res* 1994;**4**:19–28.
- 29 **Nouwen A**, Freeston MH, Cournoyer I, *et al*. Perceived symptoms and discomfort during induced bronchospasm: the role of temporal adaptation and anxiety. *Behav Res Ther* 1994;**32**:623–8.
- 30 **Turcotte H**, Boulet LP. Perception of breathlessness during early and late asthmatic responses. *Am Rev Respir Dis* 1993;**148**:514–18.
- 31 **Nowak D**, Jorres R, Martinez ML, *et al*. Effect of 3 hours of passive smoke exposure in the evening on inflammatory markers in bronchoalveolar and nasal lavage fluid in subjects with mild asthma. *Int Arch Occup Environ Health* 1997;**70**:85–93.
- 32 **Floresani AA**, Rennard SI. The role of cigarette smoke in the pathogenesis of asthma and as a trigger for acute symptoms. *Curr Opin Pulm Med* 1999;**5**:38–46.
- 33 **Bascom R**, Meggs WJ, Frampton M, *et al*. Neurogenic inflammation: with additional discussion of central and perceptual integration of nonneurogenic inflammation. *Environ Health Perspect* 1997;**105**(suppl 2):531–7.

ECHO

Screening for coeliac disease has benefits in Williams syndrome

Please visit the Archives website [www.archdischild.com] for link to this full article.

Researchers in Italy have shown that coeliac disease coexists with Williams syndrome, a disorder resulting from a deletion on chromosome 7q11.23. Among other features of Williams syndrome are gastrointestinal symptoms. Feeding problems, colic, vomiting, constipation, and recurring abdominal pain are common in young children. Unusually, however, coeliac disease has been noted before only sporadically in Williams syndrome, given that its presence is high—around 4–15%—in other chromosomal disorders such as Down syndrome and Turner syndrome.

Giannotti *et al* screened a consecutive series of 63 children (mean age 11 years) with Williams syndrome confirmed by molecular techniques for concentrations of antigliadin antibodies and antiendomysium antibodies—serological markers of coeliac disease. Coeliac disease was indicated in seven children in the series who tested positive for antigliadin and antiendomysium antibodies, and was confirmed by characteristic histological findings of villous atrophy in six who had a jejunal biopsy. All patients with confirmed coeliac disease in the series responded well to a gluten free diet.

The prevalence of coeliac disease in the series (9.6%, 6/63) was significantly higher than a published general population estimate (0.54%, 1/184) obtained from a population of more than 17 000 Italians aged 6–15 years and fell within the prevalences noted for Down and Turner syndromes.

On this basis Giannotti *et al* recommend antibody screening for coeliac disease in patients with Williams syndrome.

▲ *Journal of Medical Genetics* 2001;**38**:767–768.